BioArctic AB (BIOAb)

218.8000 -2.8000 (-1.26%)
Close SEK Disclaimer

BioArctic AB Company Profile

Equity Type
BioArctic AB (publ) develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. It also develops ABBV-0805, for treating Parkinson’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders. Further, it develops BAN1503, AD-BT2802, AD-BT2803, AD1502, AD1503, and AD2603 for the treatment of Alzheimer’s disease; ND-BT3814 andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, BAN0805, PD-BT2238, and PD1602 for the treatment of Parkinson’s disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Contact Information
Stockholm,112 51 Sweden
46 86 95 69 30
Top Executives
Konrad Beyreuther 0 0000 Member of the Scientific Board
Charlotta Ljungqvist 60 2021 Independent Director
Martin Ingelsson 0 0000 Member of Scientific Board
Pär Gellerfors 74 2003 Co-Founder, Senior VP of Business Strategy & Director
Lars Lannfelt 72 2003 Co-Founder, Senior VP of University Collaborations & Director
Ivar Verner 76 2010 Independent Vice Chairman
Cecilia Edstrom 57 2023 Independent Director
Mikael Smedeby 55 2018 Independent Director
Eugen Steiner 69 2017 Independent Chairman
Kaj Blennow 0 0000 Member of Scientific Advisory Board
Hans Wigzell 85 0000 Member of Scientific Advisory Board
Staffan Pauli 0 0000 Member of Scientific Advisory Board
Ken Marek 0 0000 Member of Scientific Advisory Board
Hakan Englund 71 2020 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles